NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026

NovaBridge will present updated Phase 1b givastomig trial results at ESMO 2026 in Spain.

What the company is saying

NovaBridge Biosciences is announcing that updated results from its Phase 1b trial of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX6 chemotherapy, will be presented at the ESMO Congress 2026 in Madrid, Spain, on October 25, 2026. The company frames givastomig as a potential first-in-class Conditional T-cell Engager and Immune Amplifier, emphasizing its design to amplify T-cell activity in CLDN18.2-expressing tumors. Phillip Dennis, MD, PhD, Chief Medical Officer, states that the upcoming data will provide a more mature view of safety, efficacy, and durability, reinforcing confidence as the program moves toward registrational development for first-line metastatic gastroesophageal adenocarcinoma. The announcement highlights that givastomig is in a global, randomized Phase 2 study (NCT07432295) following positive topline Phase 1b results, and that the FDA has granted Fast Track Designation for givastomig in combination with nivolumab and chemotherapy. The company also mentions broader applicability for givastomig in other Claudin 18.2-positive gastrointestinal cancers and identifies VIS-101 as a lead ophthalmology asset. The tone is confident and forward-looking, but specific clinical or financial results are not disclosed.

What the data suggests

The announcement provides concrete details on the timing and venue for the presentation of updated Phase 1b results: October 25, 2026, at ESMO Congress in Madrid, Spain, with Samuel J. Klempner, MD, as presenter. Givastomig is described by its mechanism and current development status, with a Phase 2 trial (NCT07432295) underway and prior positive topline Phase 1b results referenced but not detailed. The FDA Fast Track Designation for givastomig in HER2-negative advanced or metastatic gastroesophageal adenocarcinoma is confirmed. No efficacy, safety, or quantitative clinical data are disclosed in this announcement, nor are any financial figures, revenue, or R&D spend. The company signals ongoing capital-intensive clinical development but defers substantive clinical evidence to the upcoming ESMO presentation. The narrative is aspirational, with broad claims of potential applicability and first-in-class status, but the evidence base in this release is limited to trial status and regulatory milestones.

Analysis

The announcement is upbeat, emphasizing the upcoming presentation of updated Phase 1b results for givastomig and highlighting regulatory milestones such as Fast Track Designation. However, no efficacy, safety, or quantitative clinical data are disclosed—only that such data will be presented at a future conference. Most claims are forward-looking, describing the drug's design, potential applicability to other cancers, and ongoing Phase 2 evaluation, but without supporting figures or timelines for benefit realization. The language around 'potential first-in-class', 'amplify T-cell activity', and 'potential applicability' inflates the narrative relative to the actual evidence provided. The capital intensity flag is triggered by the mention of a global, randomized Phase 2 study, which implies significant ongoing R&D spend with no immediate earnings impact or disclosed financials. Overall, the gap between narrative and evidence is moderate: the company is transparent about the stage of development but uses promotional language without supporting data.

Risk flags

• ●There is a significant evidence gap between the company's claims of efficacy and safety and the actual data disclosed, as no clinical outcomes or quantitative results are provided in this announcement. This limits the ability to assess the true potential of givastomig ahead of the ESMO presentation.
• ●The ongoing Phase 2 global, randomized study signals high capital intensity and continued R&D spend, with no immediate revenue or near-term commercial returns. This exposes the company to financing and execution risk if trial results do not meet expectations.
• ●The company's narrative includes broad claims of applicability to other Claudin 18.2-positive malignancies and first-in-class status, but no supporting preclinical or clinical data for these additional indications are disclosed, raising the risk of overextension or unmet expectations.
• ●Regulatory progress is highlighted by the FDA Fast Track Designation, but this does not guarantee approval or commercial success. The pathway to market remains contingent on future clinical results and regulatory review.

Bottom line

NovaBridge is leveraging the upcoming ESMO Congress to spotlight givastomig's Phase 1b combination trial in metastatic gastroesophageal adenocarcinoma, but provides no efficacy or safety data in this release. The company's messaging is confident and emphasizes regulatory milestones, including FDA Fast Track Designation, and ongoing Phase 2 development, but investors are left waiting for substantive clinical evidence. The imminent ESMO presentation on October 25, 2026, is the next critical catalyst, as it will determine whether givastomig's safety and efficacy profile supports further investment and advancement toward registration. Until those data are disclosed, the investment case rests on regulatory momentum and the promise of the underlying mechanism, not on demonstrated clinical benefit. The main takeaway is that this is a pre-data event announcement; the real test for NovaBridge will come with the detailed results at ESMO.

Announcement summary

(NASDAQ: NBP) NovaBridge Biosciences announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6), in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA), will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. ESMO Congress 2026 is scheduled for October 23-27, 2026, in Madrid, Spain. The presentation, titled 'Expanded Safety and Efficacy of Givastomig, a Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in 1L Metastatic Gastroesophageal Carcinoma (mGEC)', will be delivered by Samuel J. Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital, on Sunday, October 25, 2026, from 12:00 p.m. to 12:45 p.m. CET in Poster Area, Hall 5. Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge, stated that givastomig is designed to amplify T-cell activity where CLDN18.2 is expressed and that the data to be shared at ESMO will provide a more mature view of safety, efficacy, and durability observed to date in combination with nivolumab and chemotherapy. Givastomig (TJ033721 / ABL111) is described as a potential first-in-class Conditional T-cell Engager and Immune Amplifier (CTIA), conditionally activating T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for the potential treatment of gastroesophageal adenocarcinoma, its current lead indication, and also has potential applicability across other Claudin 18.2+ gastrointestinal malignancies including biliary tract cancer and pancreatic ductal adenocarcinoma. Givastomig is being evaluated in a global, randomized Phase 2 study (NCT07432295), following positive topline results from a Phase 1b multicenter, open-label study in first-line metastatic gastroesophageal adenocarcinoma. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinoma in combination with nivolumab and chemotherapy. NovaBridge Biosciences is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The company's portfolio is led by givastomig and VIS-101, a tetravalent VEGF-A × ANG-2 peptibody being developed for the potential treatment of neovascular retinal diseases. The company also mentions other drug candidates, ragistomig and uliledlimab.

Disagree with this article?